 Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
| Descriptor ID |
D004354
|
| MeSH Number(s) |
E01.370.225.500.388 E05.200.500.388 E05.242.388 E05.337.550.200
|
| Concept/Terms |
Drug Screening Assays, Antitumor- Drug Screening Assays, Antitumor
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Anticancer Drug Sensitivity Tests
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Antitumor Drug Screening Assays
|
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
-
Larsen BM, Kannan M, Langer LF, Leibowitz BD, Bentaieb A, Cancino A, Dolgalev I, Drummond BE, Dry JR, Ho CS, Khullar G, Krantz BA, Mapes B, McKinnon KE, Metti J, Perera JF, Rand TA, Sanchez-Freire V, Shaxted JM, Stein MM, Streit MA, Tan YC, Zhang Y, Zhao E, Venkataraman J, Stumpe MC, Borgia JA, Masood A, Catenacci DVT, Mathews JV, Gursel DB, Wei JJ, Welling TH, Simeone DM, White KP, Khan AA, Igartua C, Salahudeen AA. A pan-cancer organoid platform for precision medicine. Cell Rep. 2021 07 27; 36(4):109429.
-
Yu L, Han S, Lang L, Song H, Zhang C, Dong L, Jia S, Zhang Y, Xiao D, Liu J, Xu Y, Zhang X. Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest. Phytomedicine. 2021 Apr; 84:153504.
-
Akbarian F, Dadkhah F, Campbell A, Asadi F, Ahangari G. Characterization of Dopamine Receptor Associated Drugs on the Proliferation and Apoptosis of Prostate Cancer Cell Lines. Anticancer Agents Med Chem. 2021; 21(9):1160-1171.
-
Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, Singh SV. Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species. PLoS One. 2011; 6(8):e23354.
-
Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin Investig Drugs. 2003 Aug; 12(8):1395-401.
-
Xu X, Shen J, Mall JW, Myers JA, Huang W, Blinder L, Saclarides TJ, Williams JW, Chong AS. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol. 1999 Nov 01; 58(9):1405-13.
-
Hong SH, Avis I, Vos MD, MartÃnez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999 May 01; 59(9):2223-8.
-
Preisler HD, Raza A, Bonomi P, Taylor S, LaFolette S, Leslie W, Lincoln S. Regrowth resistance as a likely significant contributor to treatment failure in drug-sensitive neoplastic diseases. Cancer Invest. 1997; 15(4):358-68.
-
Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, Ou D, Bonomi P, Harris JE. An in vivo inhibitor of 5-lipoxygenase, MK886, at micromolar concentration induces apoptosis in U937 and CML cells. Anticancer Res. 1996 Sep-Oct; 16(5A):2589-99.
-
Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, Oie HK, Russell EK, Ghosh BC, Pass HI, Minna JD, Mulshine JL, Ihde DC. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|